REGENXBIO Inc.

📍 Rockville, United States🗓 Founded 2008👥 410 employees💰 Last funded May 2018
Biotechnology Research🌐 regenxbio.com
Website LinkedIn
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in REGENXBIO Inc.?
REGENXBIO Inc. has 1 investors on record on gritt.io.
When did REGENXBIO Inc. last raise funding?
The most recent investment in REGENXBIO Inc. recorded on gritt.io was in May 2018.
When was REGENXBIO Inc. founded?
REGENXBIO Inc. was founded in 2008.
What industry is REGENXBIO Inc. in?
REGENXBIO Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is REGENXBIO Inc. based?
REGENXBIO Inc. is headquartered in Rockville, United States.